PRFX PainReform Corp: Enterprise Value to EBITDA Ratio
The EV/EBITDA price chart illustrating valuation trends for PainReform Ltd. (PRFX) shows a company developing new analgesics by outsourcing production and testing to third-party contractors. The current metric stands at 0.00. The business has currently reached an investment ceiling, as all funds are allocated toward regulatory compliance and research. Meanwhile, management is implementing a budget-conscious approach in an effort to prove the efficacy of its extended-release formulas.
Comprehensive metric breakdowns and analytics for painreform.com (PRFX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
PRFX - Company Profit|Expected Profit PainReform Ltd.|PRFX - Company Value to Net Income|Forward P/E Multiple PainReform Ltd.|PRFX - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple PainReform Corp|PRFX - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months PainReform|PRFX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months painreform.com|PRFX - Earnings per share increase in current year|Net earnings per share growth forecast for next year PainReform Ltd.
Fundamental valuation:PainReform Limited PRFX
To minimize risks when building a position, it is essential to evaluate the business value relative to its ability to generate cash flow. The specifics of PainReform Ltd. (PRFX) involve a high dependency on the outcomes of anesthetic clinical trials, which necessitates strict monitoring of capital expenditures. The history of the EV/EBITDA multiple—summing market capitalization and net debt, divided by operating profit—allows for a determination of the company's stability given its reliance on external financing.
Competitors of PainReform Ltd.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|Amphastar - EV/EBITDA Multiple|PCRX - EV/EBITDA Multiple|SPRY: EV/EBITDA Multiple|TBPH - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|Enterprise Value to Operating Income Before Depreciation SCPH (scPharma)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP (Tonix Pharmaceuticals Holding) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Eupraxia Pharmaceuticals, Inc. (EPRX) - Company Value to EBITDA|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio EXOZ|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entera Bio (ENTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|ABVC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cumberland Pharmaceuticals Inc. (CPIX)|Enterprise Value to EBITDA Ratio Quantum BioPharma Ltd. QNTM|FibroGen Corp - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TELO|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNYR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RLYB (rallybio.com) - Enterprise Value to EBITDA Ratio|LEXX: Enterprise Value to Operating Income Before Depreciation Ratio|PULM (Pulmatrix Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation PTHL (Pheton)|Enterprise Value to EBITDA Ratio APM (Aptorum Group Limited)|Total Company Value to Operating Income Before Depreciation Ratio lyratherapeutics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Impact BioMedical IBO|TNFA (TNF Pharmaceuticals Inc.) - Company Value to Operating Income Before Depreciation Ratio|YCBD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CYTO (Altamira Therapeutics)|LIPO: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio OPTN (optinose.com)|Enterprise Value to EBITDA Ratio PIRS|Enterprise Value to Operating Income Before Depreciation PROC (Procaps Group)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|Business Value to Operating Income Before Depreciation TFFP
